Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 13 of 18
Next
>>
>
301 to 325 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
HCC1806	AS605240	3	72	sigmoid	sigmoid	HCC1806 AS-605240 0 3 72	8	3.181	Inf	0.923	0.011	0.57	0.923	2.81	0.936	0.000257	NA	Inf	0.883	0.983	0.559	0.882	2.81	0.931	0.000333	NA
BT-549	KIN001-244	3	72	sigmoid	sigmoid	BT549 KIN001-244 0 3 72	8	1.740	Inf	0.861	0.0287	4.69	0.681	0.74	0.922	0.00047	NA	Inf	0.882	0.975	4.7	0.729	0.732	0.919	0.000531	NA
HCC38	Buparlisib	3	72	sigmoid	sigmoid	HCC38 buparlisib 0 3 72	8	1.431	0.674	-0.377	0.272	1.67	-1.0	1.21	0.991	6.94e-07	NA	1.11	0.188	0.824	1.11	0.0	1.32	0.987	2.46e-06	NA
HCC1806	TGX221	3	72	flat	flat	HCC1806 TGX-221 0 3 72	8	3.132	Inf	1.0	-0.0101	0.0	1.0	0.01	-1.16	1.0	1.01	Inf	1.0	1.02	0.0	1.0	0.01	-1.16	1.0	1.02
BT-20	AZD8055	3	72	sigmoid	sigmoid	BT20 AZD8055 0 3 72	8	2.694	0.0351	0.345	0.472	0.0116	0.313	0.89	0.934	0.000286	NA	0.0291	0.343	0.506	0.00813	0.306	0.743	0.922	0.000471	NA
HCC38	BX-912	3	72	sigmoid	sigmoid	HCC38 BX-912 0 3 72	8	1.454	0.422	-0.428	0.365	0.478	-0.433	5.0	0.993	4.02e-07	NA	0.496	0.162	0.778	0.46	0.159	5.0	0.989	1.24e-06	NA
Hs 578T	Trametinib	3		sigmoid	sigmoid	Hs578T trametinib 3	8	2.830	0.0128	0.0657	0.644	0.0112	0.0447	0.702	0.998	4.02e-09	NA	0.00864	0.168	0.366	0.00512	0.157	0.722	0.998	5.57e-09	NA
BT-549	ZSTK474	3	72	sigmoid	sigmoid	BT549 ZSTK474 0 3 72	8	1.776	0.504	0.139	0.267	0.616	-0.0912	0.836	0.996	7.06e-08	NA	0.994	0.368	0.789	0.489	0.218	0.808	0.995	9.19e-08	NA
HCC38	Alpelisib	3	72	flat	flat	HCC38 alpelisib 0 3 72	8	1.398	Inf	0.75	0.0995	0.0	0.75	0.01	0.141	0.634	0.883	Inf	0.829	0.932	0.0	0.829	0.01	0.113	0.698	0.92
BT-549	AZD-6482	3	72	sigmoid	sigmoid	BT549 AZD6482 0 3 72	8	1.744	8.87	0.616	0.0979	2.2	0.324	0.749	0.993	2.93e-07	NA	115.0	0.69	0.918	1.91	0.476	0.744	0.993	4.19e-07	NA
BT-20	Dactolisib	3	72	sigmoid	sigmoid	BT20 dactolisib 0 3 72	8	2.420	0.0111	0.024	0.639	0.00921	0.0987	1.17	0.982	6.27e-06	NA	0.0106	0.198	0.427	0.00645	0.241	1.32	0.99	9.14e-07	NA
HCC38	CAL-101	3	72	sigmoid	sigmoid	HCC38 idelalisib 0 3 72	8	1.443	Inf	0.851	0.0804	4.08	0.726	0.225	0.706	0.0254	NA	Inf	0.894	0.943	4.27	0.804	0.222	0.707	0.0252	NA
HCC1806	Torin1	3	72	sigmoid	sigmoid	HCC1806 Torin1 0 3 72	8	3.208	0.537	0.332	0.278	0.165	0.271	0.662	0.988	1.91e-06	NA	0.186	0.272	0.651	0.0697	0.26	0.75	0.992	4.55e-07	NA
HCC1806	Everolimus	3	72	sigmoid	sigmoid	HCC1806 everolimus 0 3 72	8	3.239	Inf	0.813	0.159	0.000271	0.812	0.356	0.879	0.00175	NA	Inf	0.727	0.765	0.00022	0.729	0.377	0.879	0.00177	NA
HCC38	Everolimus	3	72	sigmoid	sigmoid	HCC38 everolimus 0 3 72	8	1.437	5.11	0.511	0.429	0.000567	0.299	0.1	0.934	0.000284	NA	573000000.0	0.668	0.707	0.000349	0.53	0.1	0.932	0.000308	NA
BT-549	Torin1	3	72	sigmoid	sigmoid	BT549 Torin1 0 3 72	8	1.757	0.0123	0.026	0.659	0.0112	0.0466	1.02	0.997	3.77e-08	NA	0.0235	0.309	0.513	0.00878	0.322	1.05	0.997	1.65e-08	NA
BT-20	Buparlisib	3	72	sigmoid	sigmoid	BT20 buparlisib 0 3 72	8	2.529	0.629	-0.303	0.26	1.06	-0.565	1.46	0.994	2.13e-07	NA	0.603	0.0696	0.764	0.603	0.0	1.52	0.984	4.36e-06	NA
HCC38	Pictilisib	3	72	sigmoid	sigmoid	HCC38 pictilisib 0 3 72	8	1.420	3.12	0.499	0.129	2.45	0.0818	0.738	0.976	1.33e-05	NA	20.5	0.664	0.911	2.24	0.401	0.731	0.974	1.7e-05	NA
HCC1806	AZD-6482	3	72	flat	flat	HCC1806 AZD6482 0 3 72	8	3.201	Inf	1.0	0.00122	0.0	1.0	0.01	-0.0063	1.0	0.999	Inf	1.01	0.998	0.0	1.01	0.01	-0.00515	1.0	0.998
BT-549	AZD8055	3	72	sigmoid	sigmoid	BT549 AZD8055 0 3 72	8	1.757	0.0178	0.159	0.59	0.0122	0.145	0.913	0.942	0.000193	NA	0.0479	0.383	0.555	0.00973	0.372	0.854	0.954	9.74e-05	NA
HCC38	GDC-0980	3	72	sigmoid	sigmoid	HCC38 apitolisib 0 3 72	8	1.437	0.371	-0.0189	0.29	0.513	-0.179	0.946	0.993	3.35e-07	NA	0.96	0.359	0.808	0.393	0.295	0.998	0.993	3.51e-07	NA
HCC1806	Torin2	3	72	sigmoid	sigmoid	HCC1806 Torin2 0 3 72	8	3.212	0.0678	-0.0927	0.522	0.0798	-0.12	1.32	0.996	6.56e-08	NA	0.0486	0.079	0.492	0.0442	0.0528	1.17	0.995	1.09e-07	NA
BT-20	BX-912	3	72	flat	flat	BT20 BX-912 0 3 72	8	2.619	Inf	0.904	0.0795	0.0	0.904	0.01	0.000173	0.999	0.918	Inf	0.879	0.9	0.0	0.879	0.01	0.00619	0.982	0.896
HCC38	Omipalisib	3	72	sigmoid	sigmoid	HCC38 omipalisib 0 3 72	8	1.446	0.0145	-0.503	0.802	0.0539	-0.597	0.6	0.993	3.08e-07	NA	0.0449	0.134	0.499	0.0308	0.107	0.644	0.993	2.98e-07	NA
Hs 578T	PI103	3		sigmoid	sigmoid	Hs578T PI-103 3	8	2.807	0.321	0.175	0.26	0.231	0.163	1.21	0.991	8.05e-07	NA	0.232	0.225	0.729	0.145	0.239	1.39	0.986	2.82e-06	NA

|<
<<
Previous
Page 13 of 18
Next
>>
>
301 to 325 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)